Only in patients with bladder cancer administration of SGLT-2 inhibitors might be applied with caution as some studies observed increased numbers of this cancer entity under SGLT-2 inhibitor therapy in diabetic patients [64]. This evidence concerns the gene SLC5A2 and urinary bladder cancer.